Market Overview:
The global cancer mTOR inhibitors market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising awareness about available treatment options, and technological advancements in the field of oncology. The global cancer mTOR inhibitors market is segmented by type into Afinitor/Votubia, Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor, Torisel (Temsirolimus), Evertor andndash;. The Afinitor/Votubia segment is expected to dominate the global market during the forecast period owing to its high efficacy and safety profile. The global cancer mTOR inhibitors market is also segmented by application into Breast Cancer, Hematological Malignancy, Neuroendocrine Tumors, Hepatocellular Carcinoma and Glioblastoma. The Breast Cancer segment is expected to account for a major share of the global market during the forecast period owing to rising incidence rates of breast cancer across all regions.
Product Definition:
Cancer mTOR inhibitors are a type of cancer treatment that work by blocking the mTOR protein. mTOR is a protein that helps control cell growth and division. When it is blocked, it can stop cancer cells from growing and dividing.
Afinitor/Votubia:
Afinitor is a non-specific inhibitor of mTOR that blocks the phosphorylation of Raptor, which results in inhibition of protein synthesis. It has shown efficacy and safety in phase II clinical trials for cancer treatment. The product is currently under review by the U.S FDA and expected to be approved within two years.
Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor:
Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor and it's usage in Cancer mTOR Inhibitors market is driven by the factors such as increasing incidences of brain tumor coupled with rising awareness about the treatment among patients. According to statistics published by American Academy of Neurology, one out of every 2,500 to 4,000 children are expected to develop a brain tumor annually.
Application Insights:
The breast cancer segment dominated the global cancer mTOR inhibitors market in terms of revenue share in 2017. Breast cancer is one of the most common cancers diagnosed among women. It is also one of the most aggressive forms of cancer, with a high mortality rate and no approved cure yet. This disease has a strong genetic component and mutations in several genes have been proved to be responsible for its development, including BRCA1, BRCA2 and PALB2 gene products. These factors are expected to increase demand for mTOR inhibitor drugs during the forecast period.
Regional Analysis:
North America dominated the global cancer mTOR inhibitors market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc., Merck & Co., Inc. and Celgene Corporation, headquartered in this region. Moreover, these companies are continuously engaged in R&D activities for the development of novel drugs with improved efficacy and reduced dosage compared to existing cancer medicines.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising incidences of various types of cancers particularly brain tumors among children coupled with growing healthcare expenditure levels in emerging economies such as India and China (BMC Cancer 2016;14:58). In addition, increasing disposable income levels will boost demand for expensive treatment options thereby driving regional growth over next eight years (BMC Cancer 2016;14:58).
Growth Factors:
- Increasing incidence of cancer across the globe
- Growing awareness about cancer and its treatment options
- Rising demand for targeted therapies for cancer treatment
- Technological advancements in the field of oncology drugs development
- Availability of government funding for research and development of novel cancer therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer mTOR Inhibitors Market Research Report
By Type
Afinitor/Votubia, Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor, Torisel (Temsirolimus), Evertor andndash
By Application
Breast Cancer, Hematological Malignancy, Neuroendocrine Tumors, Hepatocellular Carcinoma, Glioblastoma
By Companies
Abraxis BioScience, Adimab, Celgene Corporation, Celator Pharmaceuticals, Eli Lilly, Exelixis, GlaxoSmithKline, HEC Pharm, Intellikine, Novartis, Abraxis BioScience, PIQUR Therapeutics, Semafore Pharmaceuticals, Takeda, Wyeth
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
159
Number of Tables & Figures
112
Customization Available
Yes, the report can be customized as per your need.
Global Cancer mTOR Inhibitors Market Report Segments:
The global Cancer mTOR Inhibitors market is segmented on the basis of:
Types
Afinitor/Votubia, Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor, Torisel (Temsirolimus), Evertor andndash
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Breast Cancer, Hematological Malignancy, Neuroendocrine Tumors, Hepatocellular Carcinoma, Glioblastoma
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abraxis BioScience
- Adimab
- Celgene Corporation
- Celator Pharmaceuticals
- Eli Lilly
- Exelixis
- GlaxoSmithKline
- HEC Pharm
- Intellikine
- Novartis
- Abraxis BioScience
- PIQUR Therapeutics
- Semafore Pharmaceuticals
- Takeda
- Wyeth
Highlights of The Cancer mTOR Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Afinitor/Votubia
- Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor
- Torisel (Temsirolimus)
- Evertor andndash
- By Application:
- Breast Cancer
- Hematological Malignancy
- Neuroendocrine Tumors
- Hepatocellular Carcinoma
- Glioblastoma
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer mTOR Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer mTOR inhibitors are drugs that block the activity of cancer-causing mTOR proteins. This can slow or stop the growth of cancer cells.
Some of the major players in the cancer mtor inhibitors market are Abraxis BioScience, Adimab, Celgene Corporation, Celator Pharmaceuticals, Eli Lilly, Exelixis, GlaxoSmithKline, HEC Pharm, Intellikine, Novartis, Abraxis BioScience, PIQUR Therapeutics, Semafore Pharmaceuticals, Takeda, Wyeth.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancer mTOR Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancer mTOR Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancer mTOR Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancer mTOR Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancer mTOR Inhibitors Market Size & Forecast, 2020-2028
4.5.1 Cancer mTOR Inhibitors Market Size and Y-o-Y Growth
4.5.2 Cancer mTOR Inhibitors Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Afinitor/Votubia
5.2.2 Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor
5.2.3 Torisel (Temsirolimus)
5.2.4 Evertor andndash
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Breast Cancer
6.2.2 Hematological Malignancy
6.2.3 Neuroendocrine Tumors
6.2.4 Hepatocellular Carcinoma
6.2.5 Glioblastoma
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancer mTOR Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancer mTOR Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Afinitor/Votubia
9.6.2 Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor
9.6.3 Torisel (Temsirolimus)
9.6.4 Evertor andndash
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Breast Cancer
9.10.2 Hematological Malignancy
9.10.3 Neuroendocrine Tumors
9.10.4 Hepatocellular Carcinoma
9.10.5 Glioblastoma
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Afinitor/Votubia
10.6.2 Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor
10.6.3 Torisel (Temsirolimus)
10.6.4 Evertor andndash
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Breast Cancer
10.10.2 Hematological Malignancy
10.10.3 Neuroendocrine Tumors
10.10.4 Hepatocellular Carcinoma
10.10.5 Glioblastoma
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Afinitor/Votubia
11.6.2 Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor
11.6.3 Torisel (Temsirolimus)
11.6.4 Evertor andndash
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Breast Cancer
11.10.2 Hematological Malignancy
11.10.3 Neuroendocrine Tumors
11.10.4 Hepatocellular Carcinoma
11.10.5 Glioblastoma
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Afinitor/Votubia
12.6.2 Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor
12.6.3 Torisel (Temsirolimus)
12.6.4 Evertor andndash
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Breast Cancer
12.10.2 Hematological Malignancy
12.10.3 Neuroendocrine Tumors
12.10.4 Hepatocellular Carcinoma
12.10.5 Glioblastoma
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Afinitor/Votubia
13.6.2 Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor
13.6.3 Torisel (Temsirolimus)
13.6.4 Evertor andndash
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Breast Cancer
13.10.2 Hematological Malignancy
13.10.3 Neuroendocrine Tumors
13.10.4 Hepatocellular Carcinoma
13.10.5 Glioblastoma
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancer mTOR Inhibitors Market: Competitive Dashboard
14.2 Global Cancer mTOR Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abraxis BioScience
14.3.2 Adimab
14.3.3 Celgene Corporation
14.3.4 Celator Pharmaceuticals
14.3.5 Eli Lilly
14.3.6 Exelixis
14.3.7 GlaxoSmithKline
14.3.8 HEC Pharm
14.3.9 Intellikine
14.3.10 Novartis
14.3.11 Abraxis BioScience
14.3.12 PIQUR Therapeutics
14.3.13 Semafore Pharmaceuticals
14.3.14 Takeda
14.3.15 Wyeth
